Moncef Slaoui is known for his background in biotechnology, particularly his role as the former Chairman of the Board at Vaxcyte, Inc., where he served from July 2017 to March 2021. During his time at Vaxcyte, Dr. Slaoui was deeply...

Moncef Slaoui is known for his background in biotechnology, particularly his role as the former Chairman of the Board at Vaxcyte, Inc., where he served from July 2017 to March 2021. During his time at Vaxcyte, Dr. Slaoui was deeply involved in the development of the company's vaccine candidates and was part of the shift towards innovative solutions in the pharmaceutical space. However, he faced significant challenges during his leadership. In March 2021, he resigned amid allegations of inappropriate conduct from his past employment at GlaxoSmithKline, where he had previously served in high-ranking roles. Despite this controversy, Dr. Slaoui's expertise and experience in the biopharmaceutical industry remain significant. He has a track record of driving company initiatives and navigating complex industry challenges, and though he left Vaxcyte under challenging circumstances, his contributions to advancing vaccine development are notable.

Quick Links

1. Rivals

2. Holdings

3. Insider Trading

4. Compensation History

5. Other Vaxcyte, Inc. CEOs

V

Moncef Slaoui

Ex-CEO of Vaxcyte, Inc.

Field of Expertise

Healthcare & Life Sciences - Biotechnology

Sector of Economy

Healthcare

CEO of Vaxcyte, Inc. for

3 years 8 months (Jul 2017 - Mar 2021)

Previous Experience

Former employee of GlaxoSmithKline, extensive experience in vaccine development and biotechnology.

Rivals

Competitors/colleagues of Moncef Slaoui

Holdings

See how much did Moncef Slaoui make over time.

Moncef Slaoui's investment in Vaxcyte reflected his belief in the company's potential. He held substantial stock options, with over 119,000 options outstanding at the end of 2020. His confidence peaked as Vaxcyte neared significant pipeline milestones. However, following his resignation...

Moncef Slaoui's investment in Vaxcyte reflected his belief in the company's potential. He held substantial stock options, with over 119,000 options outstanding at the end of 2020. His confidence peaked as Vaxcyte neared significant pipeline milestones. However, following his resignation in March 2021, his holdings were scrutinized, and the value fluctuated as Vaxcyte’s stock responded to market dynamics and the company's developments. While his financial stake was initially seen as a positive sign of alignment with shareholder interests, the shift in his public role caused some uncertainty regarding future company performance and valuation.

Insider Trading

See recent insider trades of Moncef Slaoui.

No insider trades found for this CEO.

Compensation History

See how much did Moncef Slaoui make over time.

In 2021, Moncef Slaoui's compensation at Vaxcyte totaled about $938,000, mainly through a salary of $574,800 and a performance-based bonus of $363,561. His compensation plan aimed to align his goals with the company's strategic objectives, particularly focusing on advances in vaccine development programs like VAX-24. In 2020, his total compensation was slightly lower at $784,883, and he did not receive any vested stock that year as the emphasis was on cash compensation. Despite being compensated well for leadership, the circumstances surrounding his exit raised questions about the effectiveness of such an arrangement in fostering long-term trust and performance. Slaoui's compensation reflects the high stakes and demands of leading in the biopharmaceutical field, where success often directly impacts public health.

Year

2021

Total Compensation

$938.36K

Salary

$574.80K

Board Justification

The compensation program aims to attract, retain and reward highly-qualified executives while providing incentives that motivate and reward for achievement of key performance goals, aligning executives’ interests with those of stockholders.

Bonus

$363.56K

Board Justification

The annual performance-based cash bonus awards provide incentive compensation that is specifically designed to motivate our executive officers to achieve pre-established, company-wide priorities set by the Compensation Committee and to reward them for results and achievements in a given year.

Other

$0.00

Board Justification

No other compensation was provided outside of salary, bonus, and stock options.

Restricted Stock

$0.00(0 N/A)

Board Justification

No stock was vested in 2021 as the focus is on cash compensation and performance-based bonuses.

Performance Metrics

The performance metrics for the CEO's compensation were based on the achievement of corporate goals related to the VAX-24 program and other pipeline programs.

Other Vaxcyte, Inc. CEOs

Here are other CEOs of Vaxcyte, Inc.

Grant Pickering

CEO of Vaxcyte, Inc.

May 2020 - Present